Highly Efficient Expression of Interleukin-2 under the Control of Rabbit beta-Globin Intron II Gene Enhances Protective Immune Responses of Porcine Reproductive and Respiratory Syndrome (PRRS) DNA Vaccine in Pigs

文献类型： 外文期刊

第一作者： Qi, Jing

作者： Qi, Jing;Chen, Lei;Cong, Xiaoyan;Wang, Jinbao;Du, Yijun;Qi, Jing;Liu, Jiyu;Wu, Jiaqiang;Guo, Lihui;Liu, Junzhen;Tao, Haiying;Sun, Wenbo;Chen, Lei;Cong, Xiaoyan;Ren, Sufang;Shi, Jianli;Li, Jun;Wang, Jinbao;Huang, Baohua;Lu, Yu;Wang, Xinglong;Hu, Yue;Wang, Jinbao;Li, Feng

作者机构：

期刊名称：PLOS ONE （ 影响因子：3.24； 五年影响因子：3.788 ）

ISSN： 1932-6203

年卷期： 2014 年 9 卷 3 期

页码：

收录情况： SCI

摘要： Highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) had caused catastrophic losses in swine industry in China. The current inactivated vaccine provided only limited protection, and the attenuated live vaccine could protect piglets against the HP-PRRSV but there was a possibility that the attenuated virus returned to high virulence. In this study, the eukaryotic expression vector pVAX1 (c) was modified under the control of rabbit beta-globin intron II gene and the modified vector pMVAX1 (c) was constructed. Porcine interleukin-2 (IL-2) and GP3-GP5 fusion protein of HP-PRRSV strain SD-JN were highly expressed by pMVAX1 (c). Mice inoculated with pMVAX1 (c)-GP35 developed significantly higher PRRSV-specific antibody responses and T cell proliferation than those vaccinated with pVAX1 (c)-GP35. pMVAX1 (c)-GP35 was selected as PRRS DNA vaccine candidate and co-administrated with pVAX1 (c)-IL-2 or pMVAX1 (c)-IL-2 in pigs. pMVAX1 (c) -IL-2+pMVAX1 (c)-GP35 could provide enhanced PRRSV-specific antibody responses, T cell proliferation, Th1-type and Th2-type cytokine responses and CTL responses than pMVAX1 (c)-GP35 and pVAX1 (c)-IL-2+pMVAX1 (c)-GP35. Following homologous challenge with HP-PRRSV strain SD-JN, similar with attenuated PRRS vaccine group, pigs inoculated with pMVAX1 (c)-IL-2+pMVAX1 (c)-GP35 showed no clinical signs, almost no lung lesions and no viremia, as compared to those in pMVAX1 (c)-GP35 and pVAX1 (c)-IL-2+pMVAX1 (c)-GP35 groups. It indicated that pMVAX1 (c)-IL-2 effectively increases humoral and cell mediated immune responses of pMVAX1 (c)-GP35. Co-administration of pMVAX1 (c)-IL-2 and pMVAX1 (c)-GP35 might be attractive candidate vaccines for preventing HP-PRRSV infections.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序